Sanofi to review its new eczema drug amlitelimab - Meet them in May

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study - Meet them in May

J&J eyes $100B in sales amid gains for cancer, immune drugs - Meet them in May

Alumis soars as TYK2 drug hits mark in psoriasis trials - Meet them in May

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Connect’s Dupixent challenger hits the mark in phase 3 eczema trial

Apogee strengthens case for longer-lasting eczema drug

Braham Shroot

Senior Scientific Advisor SOLTEGO

Thursday 21st May 2026

Salt Inducible Kinase Inhibitors: A Novel Approach for Next-Generation Topical Therapies

2:00 pm

Explore the potential of proprietary topical SIK inhibitors supported by in vitro, ex vivo, and early human data to deliver differentiated Topical Therapies
Discover how bioassays and skin penetration studies are enabling targeted topical delivery with favorable safety and pharmacologic properties to profile potential therapeutic indications
Learn how integrated pharmacology, toxicology, and transcriptomic approaches are being used to de-risk next-generation therapeutics before full development